Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas

View Full Paper
Ask AI
Bookmark
Share

Authors

HLHwan LeeJSJakub SvobodaCDChristopher R. D’Angelo

Discussion

Loading...

Member takes

Overview

Phase IIa trial shows bispecific antibodies enhance CAR T-cell therapy, improving complete response rates in relapsed lymphomas, implying potential benefits for patients.

Key Points

  • Complete response rates improved by early administration of bispecific antibodies after CAR-T therapy.
  • Overall response rate reached 67% in the mosunetuzumab cohort, with median follow-up over 3 years.
  • Observational data indicates increased CAR-T cell expansion in blood post bispecific antibody treatment.
  • Treatment appears safe with manageable adverse events, including cytokine release syndrome, across cohorts.

Cite This Study

Lee et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d58ehttps://doi.org/10.1182/blood-2025-1952
View Full Paper
Ask AI
Bookmark
Share